PReS-FINAL-2310: Successful rituximab treatment in a 14 year-old boy with lupus nephritis by unknown
POSTER PRESENTATION Open Access
PReS-FINAL-2310: Successful rituximab treatment
in a 14 year-old boy with lupus nephritis
V Torrente-Segarra*, E Iglesias, R Bou, S Ricart, MI Gonzalez, J Sanchez, L Lopez-Vives, J Antón-López
From 20th Pediatric Rheumatology European Society (PReS) Congress




to present the case of a child with refractory lupus
nephritis that responded to rituximab therapy in a sys-
temic lupus erythematosus (SLE) child.
Methods
we describe sociodemographic, clinical and laboratory
follow-up of a 14-yo boy with lupus nephritis. Treat-
ment was based in Euro-Lupus recommendations. We
collected all data from patient’s chart from our database
at Hospital Sant Joan de Déu, in Esplugues Llobregat
(Catalunya, Spain). From the follow-up clinical charts
we collected sociodemographics, specific SLE serological
profile, proteinuria level, and treatment received.
Results
a 12-yo boy was initially visited in our Clinics due to the
presence of ANA low titre (1/40) and recurrent general-
ized arthralgia, in association to livedo reticularis.
Neither DNAds positivity nor evidence of inflammatory
pattern of his arthralgia was found. Two years later
(April’10) showed up with following symptoms: fever,
blaschkitis, ANA 1/160, DNAds positivity (low titre), Sm
positivity, hypocomplementemia, and mild plaketopenia.
Active urine sediment was also found: proteinuria and
hematuria (+++). We performed a complete 24 h urine
test, showing 2.4 g/24 h proteinuria. SLEDAI score was
14. Patient was immmediatly admitted and a renal
biopsy was performed. It showed Class IV-WHO-Lupus
Nephritis (LN) with 17/24 and 0/12 activity and chroni-
city scores, respectively.
The patient initiated therapy with hydroxyclorochine
(2 mg/kg/d), prednisone (1 mg/kg/d) and 3 cychlopho-
sphamide pulses, and hyposodic diet; however, no
improvement was observed after 2 months. Then, myco-
phenolate acid was added, reaching 720 mg/daily, with
no improvement after another 2 months. In July ‘10 the
patient received the first of 4 doses of rituximab (375
mg/m2/every other week). We also initiated prophylaxis
treatment for P. carinii. After 2 months, proteinuria dra-
matically improved. Although proteinuria descended to
2 g/24 h we performed a re-biopsy in October’10 due to
the persistence of the proteinuria: Class IV-WHO-Lupus
Nephritis was also observed, and chronicity index was
6/24 and activity index was 4/12. All the other serologi-
cal parameters were also improved. In December’10
patient reached proteinuria <500 mg/24 h, normal
values in all activity and serological parameters. SLEDAI
score was 0. We started to taper steroids. In the last fol-
low-up visit patient maintained clinical remission receiv-
ing: hydroxychloroquine, mycophenolate acid, and 5 mg
prednisone daily. Neither infections nor adverse events
after 2 years of rituximab treatment have been observed.
Conclusion
we describe a case of refractory LN successfully treated
with rituximab. Conventional treatments fail to control
LN disease. Rituximab offers an alternative for severe
patients who do not respond to immunosuppressant.
Rituximab seems to provide a good safety profile. Larger
series are needed to confirm this data in juvenile SLE.
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